Staburo provided statistical support for a biomarker study that was recently published in the Journal Lung Cancer. The manuscript describes a retrospective analysis to assess the ability of the VeriStrat serum protein test to predict clinical benefit with afatinib versus erlotinib (predictive effect), and the association of VeriStrat status with overall clinical outcomes (prognostic effect) in LUX-Lung 8.


Highlights of the publication
  • Clinical utility of the VeriStrat serum protein test was assessed in LUX-Lung 8.
  • Patients were classified as VeriStrat ‘Good’ (VS-G) or VeriStrat ‘Poor’ (VS-P).
  • VS-G classification is associated with favorable survival outcomes versus VS-P.
  • In VS-G patients, survival outcomes are superior with afatinib versus erlotinib.

The full publication can be read here: